MARTINSRIED/MUNICH Germany, WALTHAM, Mass. and PRINCETON, N.J., Nov. 2
/PRNewswire-FirstCall/ -- GPC Biotech AG (Frankfurt Stock Exchange: GPC;
TecDAX index; Nasdaq: GPCB) today announced that the Company will hold an
analyst and press meeting in Frankfurt, Germany to discuss financial
results for the third quarter and first nine months of 2006 and to provide
a business update.
The meeting, which will be conducted in English, will be held Thursday,
November 9, 2006 at 2 PM CET/8 AM EST at the Maritim Hotel in Frankfurt.
The meeting will also be accessible via telephone or webcast. The live
webcast, including synchronized slides, will be available on the GPC
Biotech Web site at http://www.gpc-biotech.com. A replay will be available
via the Web site following the live event.
Dial-in numbers for the analyst and press meeting are as follows:
Participants from Europe: 0049 (0)69 5007 1307 or
0044 (0)20 7806 1955
Participants from the U.S.: 1-718-354-1388
Please dial in 10 minutes before the beginning of the meeting.
GPC Biotech AG is a publicly traded biopharmaceutical company focused
on discovering, developing and commercializing new anticancer drugs. GPC
Biotech's lead product candidate -- satraplatin -- is an oral
platinum-based compound that has shown highly statistically significant
results for progression-free survival in a Phase 3 registrational trial as
a second-line chemotherapy treatment in hormone-refractory prostate cancer.
The U.S. FDA has granted fast track designation to satraplatin for this
indication, and the rolling NDA submission process for this compound is
underway. GPC Biotech is also developing a monoclonal antibody with a novel
mechanism-of-action against a variety of lymphoid tumors, currently in
Phase 1 clinical development, and has ongoing drug development and
discovery programs that leverage its expertise in kinase inhibitors. GPC
Biotech AG is headquartered in Martinsried/Munich (Germany), and its wholly
owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton,
New Jersey. For additional information, please visit GPC Biotech's Web site
at http://www.gpc-biotech.com.
This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of GPC Biotech AG,
including summary statements relating to topline results of the SPARC trial
and summary statements relating to the potential efficacy and safety
profile of satraplatin. Such statements are based on current expectations
and are subject to risks and uncertainties, many of which are beyond our
control, that could cause future results, performance or achievements to
differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Actual results
could differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking statements
contained in this press release. In particular, there can be no guarantee
that topline results from the clinical trial discussed in this press
release will be confirmed upon full analysis of the results of the trial
and additional information relating to the safety, efficacy or tolerability
of satraplatin may be discovered upon further analysis of data from the
SPARC trial or analysis of additional data from other ongoing clinical
trials for satraplatin. Furthermore, even if these topline results are
confirmed upon full analysis of the trial, we cannot guarantee that
satraplatin will be approved for marketing in a timely manner, if at all,
by regulatory authorities nor that, if marketed, satraplatin will be a
successful commercial product. We direct you to GPC Biotech's Annual Report
on Form 20-F for the fiscal year ended December 31, 2005 and other reports
filed with the U.S. Securities and Exchange Commission for additional
details on the important factors that may affect the future results,
performance and achievements of GPC Biotech. Forward-looking statements
speak only as of the date on which they are made and GPC Biotech does not
undertake any obligation to update these forward-looking statements, even
if new information becomes available in the future.
The scientific information discussed in this press release related to
satraplatin is preliminary and investigative. Satraplatin has not yet been
approved by the FDA in the U.S., the EMEA in Europe or any other regulatory
authority and no conclusions can or should be drawn regarding its safety or
effectiveness. Only the relevant regulatory authorities can determine
whether satraplatin is safe and effective for the use(s) being
investigated.
For further information, please contact:
GPC Biotech AG
Martin Braendle
Director, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com
In the U.S.:
Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 781-890-9007 X267
usinvestors@gpc-biotech.com
SOURCE GPC Biotech AG
 back to top
Related links:
http://www.gpc-biotech.com/
CONTACT:
Martin Braendle, Director, Investor Relations
& Corporate Communications of GPC Biotech AG, +49 (0)89
8565-2693, ir@gpc-biotech.com, or In the U.S.: Laurie Doyle,
Director, Investor Relations & Corporate Communications,
+1-781-890-9007 ext. 267, usinvestors@gpc-biotech.com, both of
GPC Biotech AG
|
